A new milestone in Hep B prevention has been achieved. Yesterday, on November 9th, the FDA approved HEPLISAV-B, the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults. Dynavax expects to commercially launch HEPLISAV-B in the United States in the first quarter of 2018.
This 2 shot vaccine could greatly increase successful vaccination rates given almost half of adults fail to complete the hepatitis B vaccination series within one year. Decreasing the number of shots could greatly increase completion of the series.
More info here: http://investors.dynavax.com/releasedetail.cfm?ReleaseID=1048181